|
1
|
Stone NJ, Robinson JG, Lichtenstein AH,
Merz CN Bairey, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D,
Lloyd-Jones DM, et al: American College of Cardiology/American
Heart Association Task Force on Practice Guidelines: 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: A report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines. Circulation. 129(Suppl 2): S1–S45.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jacobson TA, Ito MK, Maki KC, Orringer CE,
Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, et al:
National Lipid Association recommendations for patient-centered
management of dyslipidemia: Part 1 - executive summary. J Clin
Lipidol. 8:473–488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anderson TJ, Grégoire J, Hegele RA,
Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC,
Grover S, et al: 2012 update of the Canadian Cardiovascular Society
guidelines for the diagnosis and treatment of dyslipidemia for the
prevention of cardiovascular disease in the adult. Can J Cardiol.
29:151–167. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grundy SM: Expert Dyslipidemia Panel: An
International Atherosclerosis Society Position Paper: Global
recommendations for the management of dyslipidemia. J Clin Lipidol.
7:561–565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Noto D, Cefalù AB and Averna MR: Beyond
statins: New lipid lowering strategies to reduce cardiovascular
risk. Curr Atheroscler Rep. 16:4142014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blom DJ, Hala T, Bolognese M, Lillestol
MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM,
et al: DESCARTES Investigators: A 52-week placebo-controlled trial
of evolocumab in hyperlipidemia. N Engl J Med. 370:1809–1819. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Robinson JG, Nedergaard BS, Rogers WJ,
Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P,
Scott R, et al: LAPLACE-2 Investigators: Effect of evolocumab or
ezetimibe added to moderate- or high-intensity statin therapy on
LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2
randomized clinical trial. JAMA. 311:1870–1882. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koren MJ, Lundqvist P, Bolognese M, Neutel
JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM and Bays H:
MENDEL-2 Investigators: Anti-PCSK9 monotherapy for
hypercholesterolemia: The MENDEL-2 randomized, controlled phase III
clinical trial of evolocumab. J Am Coll Cardiol. 63:2531–2540.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stroes E, Colquhoun D, Sullivan D, Civeira
F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, et
al: GAUSS-2 Investigators: Anti-PCSK9 antibody effectively lowers
cholesterol in patients with statin intolerance: The GAUSS-2
randomized, placebo-controlled phase 3 clinical trial of
evolocumab. J Am Coll Cardiol. 63:2541–2548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Raal FJ, Stein EA, Dufour R, Turner T,
Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D,
et al: RUTHERFORD-2 Investigators: PCSK9 inhibition with evolocumab
(AMG 145) in heterozygous familial hypercholesterolaemia
(RUTHERFORD-2): A randomised, double-blind, placebo-controlled
trial. Lancet. 385:331–340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stroup DF, Berlin JA, Morton SC, Olkin I,
Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker
SB: Meta-analysis of observational studies in epidemiology: A
proposal for reporting. Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) group. JAMA. 283:2008–2012. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song F, Altman DG, Glenny AM and Deeks JJ:
Validity of indirect comparison for estimating efficacy of
competing interventions: Empirical evidence from published
meta-analyses. BMJ. 326:4722003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giugliano RP, Desai NR, Kohli P, Rogers
WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald
ST, et al: Efficacy, safety, and tolerability of a monoclonal
antibody to proprotein convertase subtilisin/kexin type 9 in
combination with a statin in patients with hypercholesterolaemia
(LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging,
phase 2 study. Lancet. 380:2007–2017. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roth EM, Taskinen MR, Ginsberg HN,
Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R and
Baccara-Dinet MT: Monotherapy with the PCSK9 inhibitor alirocumab
versus ezetimibe in patients with hypercholesterolemia: Results of
a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol.
176:55–61. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Robinson JG, Farnier M, Krempf M, Bergeron
J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M,
et al: ODYSSEY LONG TERM Investigators: Efficacy and safety of
alirocumab in reducing lipids and cardiovascular events. N Engl J
Med. 372:1489–1499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moriarty PM, Jacobson TA, Bruckert E,
Thompson PD, Guyton JR, Baccara-Dinet MT and Gipe D: Efficacy and
safety of alirocumab, a monoclonal antibody to PCSK9, in
statin-intolerant patients: Design and rationale of ODYSSEY
ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 8:554–561.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raal FJ, Giugliano RP, Sabatine MS, Koren
MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM,
et al: Reduction in lipoprotein(a) with PCSK9 monoclonal antibody
evolocumab (AMG 145): A pooled analysis of more than 1,300 patients
in 4 phase II trials. J Am Coll Cardiol. 63:1278–1288. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
1Sabatine MS, Giugliano RP, Wiviott SD,
Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J,
Wasserman SM, et al: Open-Label Study of Long-Term Evaluation
against LDL Cholesterol (OSLER) Investigators: Efficacy and safety
of evolocumab in reducing lipids and cardiovascular events. N Engl
J Med. 372:1500–1509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raal F, Scott R, Somaratne R, Bridges I,
Li G, Wasserman SM and Stein EA: Low-density lipoprotein
cholesterol-lowering effects of AMG 145, a monoclonal antibody to
proprotein convertase subtilisin/kexin type 9 serine protease in
patients with heterozygous familial hypercholesterolemia: The
Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial
Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Circulation. 126:2408–2417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koren MJ, Scott R, Kim JB, Knusel B, Liu
T, Lei L, Bolognese M and Wasserman SM: Efficacy, safety, and
tolerability of a monoclonal antibody to proprotein convertase
subtilisin/kexin type 9 as monotherapy in patients with
hypercholesterolaemia (MENDEL): A randomised, double-blind,
placebo-controlled, phase 2 study. Lancet. 380:1995–2006. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sullivan D, Olsson AG, Scott R, Kim JB,
Xue A, Gebski V, Wasserman SM and Stein EA: Effect of a monoclonal
antibody to PCSK9 on low-density lipoprotein cholesterol levels in
statin-intolerant patients: The GAUSS randomized trial. JAMA.
308:2497–2506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirayama A, Honarpour N, Yoshida M,
Yamashita S, Huang F, Wasserman SM and Teramoto T: Effects of
evolocumab (AMG 145), a monoclonal antibody to PCSK9, in
hypercholesterolemic, statin-treated Japanese patients at high
cardiovascular risk - primary results from the phase 2 YUKAWA
study. Circ J. 78:1073–1082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Urban D, Pöss J, Böhm M and Laufs U:
Targeting the proprotein convertase subtilisin/kexin type 9 for the
treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol.
62:1401–1408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Banach M, Rizzo M, Obradovic M, Montalto
G, Rysz J, Mikhailidis DP and Isenovic ER: PCSK9 inhibition - a
novel mechanism to treat lipid disorders? Curr Pharm Des.
19:3869–3877. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dias CS, Shaywitz AJ, Wasserman SM, Smith
BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert
A, et al: Effects of AMG 145 on low-density lipoprotein cholesterol
levels: Results from 2 randomized, double-blind,
placebo-controlled, ascending-dose phase 1 studies in healthy
volunteers and hypercholesterolemic subjects on statins. J Am Coll
Cardiol. 60:1888–1898. 2012. View Article : Google Scholar : PubMed/NCBI
|
